2 hours ago
1
Josh Kohn-Lindquist, The Motley Fool
Wed, May 20, 2026 astatine 10:15 AM CDT 3 min read
Shares of immunotherapy biotech ImmunityBio (NASDAQ: IBRX) initially popped today, and are up 9% arsenic of 10:45 a.m. ET connected Wednesday. After marketplace adjacent yesterday, ImmunityBio announced that the Food and Drug Administration (FDA) had accepted the company's supplemental biologics licence exertion (BLA) for review, which could pb to a large statement enlargement for its halfway treatment, Anktiva.
Currently, ImmunityBio's flagship Anktiva cause is approved to dainty patients with bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) who person Carcinoma successful Situ (CIS). The caller BLA would grow Anktiva's statement to include its usage successful treating BCG-unresponsive NMIBC cases with papillary disease, successful summation to CIS. Plenty of method presumption here, but this could beryllium a large woody for ImmunityBio, truthful it is worthy looking into for the pursuing reason.
Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected a little-known company, called an "Indispensable Monopoly," providing the captious exertion Nvidia and Intel some need.
In the property release, absorption noted, "Approximately 85% of the 64,000 radical diagnosed with NMIBC successful the U.S. each twelvemonth contiguous with papillary disease." Papillary illness is overmuch much communal than CIS, truthful this could greatly grow ImmunityBio's people marketplace arsenic it continues to turn its attraction indications. Since "CIS and papillary illness originate from the aforesaid cancer-inducing clone," galore doctors person already been treating patients off-label with Anktiva. An FDA support would origin insurers to screen the attraction going forward.
The FDA acceptable a Prescription Drug User Fee Act (PDUFA) people enactment day for Jan. 6, 2027, truthful investors volition privation to support this day successful caput going forward. In summation to its bladder crab treatments, ImmunityBio has a beardown pipeline of objective trials spanning lung and ovarian cancer, HIV, glioblastoma, Non-Hodgkin Lymphoma, and more. That said, ImmunityBio's banal has much than quadrupled twelvemonth to day and presently trades astatine 58 times sales, truthful a batch of this imaginable is already priced into the company's valuation. Investors would beryllium omniscient not to spell "all-in" astatine erstwhile if they're funny successful the promising biotech, but alternatively to marque smaller bets implicit time.
Should you bargain banal successful ImmunityBio close now?
Before you bargain banal successful ImmunityBio, see this:
The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and ImmunityBio wasn’t 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.
English (CA) · 
English (US) · 
Spanish (MX) ·